Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2007

Dyax and Glenmark Jointly Pursue Discovery of Therapeutic Antibodies

  • Dyax and Glenmark Pharmaceuticals will work together to discover therapeutic antibodies. Dyax will perform funded research to identify antibodies for three targets provided by Glenmark. Furthermore, these research activities may be expanded to include additional targets.

    Dyax will receive technology license fees and full time employee payments from Glenmark for the research as well as clinical milestone payments and royalties on net sales that may result from Glenmark’s development and commercialization of antibodies from Dyax’s libraries. The agreement also provides Glenmark with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s technology.

    “This is a very important step in Glenmark’s entry in the field of novel biologics research,” remarks Glenn Saldanha, managing director and CEO of Glenmark. “Oncology and inflammation are areas of large unmet medical needs. Our strategy to supplement NCE research with biologics research would allow us to build a strong pipeline in this area.

    “We expect the first biologic product from Glenmark to enter clinics in 2009.”



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »